Robbins Umeda LLP Announces an Investigation of the Acquisition of King Pharmaceuticals, Inc. by Pfizer, Inc.

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors (“Board”) of King Pharmaceuticals, Inc. (“King” or the “Company”) (NYSE: KG) in connection with their efforts to sell King to Pfizer, Inc. (“Pfizer”) (NYSE: PFE).  If the transaction is completed, King shareholders will receive $14.25 in cash for each share of King common stock they hold.

Robbins Umeda LLP’s investigation concerns whether King’s Board undertook a fair process to obtain fair consideration for all shareholders of King.  Specifically, our investigation concerns whether the Company’s Board breached their fiduciary duties to King shareholders by failing to adequately shop the Company before entering into the transaction with Pfizer.

If you are a shareholder of King, plan to continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at info@robbinsarroyo.com.

    Send This Post

    Tags: